

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact [ehp508@niehs.nih.gov](mailto:ehp508@niehs.nih.gov). Our staff will work with you to assess and meet your accessibility needs within 3 working days.

### **Supplemental Material**

#### **Associations of Prenatal Per- and Polyfluoroalkyl Substance (PFAS) Exposures with Offspring Adiposity and Body Composition at 16–20 Years of Age: Project Viva**

Mingyu Zhang, Sheryl L. Rifas-Shiman, Izzuddin M. Aris, Abby F. Fleisch, Pi-I Debby Lin, Amy R. Nichols, Emily Oken, and Marie-France Hivert

#### **Table of Contents**

**Table S1.** Akaike Information Criterion (AIC) for the multivariable-adjusted regression models that estimate the associations of maternal individual PFAS with child BMI in late adolescence ( $n = 545$ ).

**Table S2.** Distributions of log<sub>2</sub>-transformed prenatal PFAS levels for Project Viva participants included in this analysis ( $n = 545$ ).

**Table S3.** Characteristics of Project Viva mothers and children included in the main analysis ( $n = 545$ ) vs. excluded ( $n = 1583$ ).

**Table S4.** Prenatal PFAS levels by select maternal and child characteristics ( $n = 545$ ).

**Table S5.** Distributions and sample sizes of adiposity and body composition measures in late adolescence, overall and stratified by child sex ( $n = 439$  to  $545$ ).

**Table S6.** Multivariable-adjusted overall effects (estimates and 95% credible intervals) of prenatal PFAS mixtures estimated by the differences in probit of the probability of obesity, BMI, and DXA measures in late adolescence when all PFAS are in their 10<sup>th</sup> to 90<sup>th</sup> percentile (with an interval of 10 percentile) as compared to when they are in their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 545$  for obesity and BMI;  $n = 439$  for DXA measures).

**Table S7.** Posterior inclusion probabilities for prenatal PFAS in the multivariable-adjusted Bayesian kernel machine regression models with component-wise variable selection ( $n = 545$  for obesity and BMI;  $n = 439$  for DXA measures).

**Table S8.** Multivariable-adjusted associations (estimates and 95% confidence intervals) of prenatal PFAS mixtures with obesity risk, BMI, and DXA measures in late adolescence estimated using quantile g-computation models (n = 439 to 545). Estimates show the differences in continuous values of BMI and DXA measures or relative risks of obesity (yes vs. no) per each quartile increment of the PFAS mixture.

**Table S9.** Multivariable-adjusted associations (estimates and 95% confidence intervals) of prenatal PFAS levels with adiposity and body composition measures in late adolescence, overall and stratified by child sex (n = 439 to 545). Estimates show the differences in continuous values of adiposity and body composition measures or relative risks of obesity (yes vs. no) per doubling of PFAS levels.

**Table S10.** Associations (estimates and 95% confidence intervals) of prenatal PFAS levels with adiposity and body composition measures in late adolescence after: 1) removing maternal pre-pregnancy body mass index from the multivariable-adjusted models; 2) additionally adjusted for first-trimester albumin; 3) additionally adjusted for first-trimester DASH diet scores; and 4) additionally adjusted for urbanicity scores (n = 522 to 545; sample size varies by models due to missing covariates). Estimates show the differences in continuous values of adiposity and body composition measures or relative risks of obesity (yes vs. no) per doubling of prenatal PFAS levels.

**Table S11.** Associations (estimates and 95% confidence intervals) of prenatal PFAS levels with adiposity and body composition measures in late adolescence after using the stabilized inverse probability weighting method to account for potential selection bias (n = 545).

**Figure S1.** Participant selection flowchart (n = 545).

**Figure S2.** Distributions of PFAS (ng/mL) measured in maternal plasma samples collected in the first trimester during pregnancy (n = 545). PFAS concentrations below the LOD (provided in Table 1) were imputed using  $LOD/\sqrt{2}$ .

**Figure S3.** Directed Acyclic Graphs (DAG) showing the hypothesized relationships between all variables in this analysis. DAGs were created on dagitty.net.

**Figure S4.** Spearman correlation matrix for adiposity and body composition measures in late adolescence. Sample sizes for each measure are provided in Table S5. Correlation between each pair of adiposity measures is computed using all complete pairs of observations on these measures. Color intensity is proportional to the correlation coefficients.

**Figure S5.** Multivariable-adjusted associations between individual prenatal PFAS and BMI ( $\text{kg}/\text{m}^2$ ) in late adolescence estimated using (A) linear regression, (B) quantile g-computation, and (C) Bayesian kernel machine regression ( $n = 545$ ). Panel A shows the differences and 95% confidence intervals of BMI per doubling of PFAS levels (estimates are provided in Table 3 [Adjusted]). Panel B shows the weights for each PFAS that correspond to the proportion of the overall effect of all PFAS on BMI in the positive or negative direction (positive and negative weights, respectively, add up to 1, representing the proportion of the overall effect and the relative importance of each mixture component within each direction; the shading of bars represents the overall effect size within each direction, with darker shades indicating a larger effect compared to lighter shades; estimates are provided in Table S8). Panel C shows the estimates and 95% credible intervals of PFAS with BMI when all other PFAS are fixed at their 50<sup>th</sup> percentile.

**Figure S6.** Overall effects of prenatal PFAS mixtures estimated by the differences in (A) DXA percentage fat; (B) DXA fat mass index ( $\text{kg}/\text{m}^2$ ); (C) DXA trunk fat mass index ( $\text{kg}/\text{m}^2$ ); and (D) DXA lean mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence when all PFAS are in their 10<sup>th</sup> to 90<sup>th</sup> percentile (with an interval of 10 percentile) as compared to when they are in their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 439$ ).

**Figure S7.** Multivariable-adjusted associations between individual prenatal PFAS and DXA percentage fat in late adolescence estimated using (A) linear regression, (B) quantile g-computation, and (C) Bayesian kernel machine regression ( $n = 439$ ). Panel A shows the differences and 95% confidence intervals of DXA percentage fat per doubling of PFAS levels (estimates are provided in Table 3 [Adjusted]). Panel B shows the weights for each PFAS that correspond to the proportion of the overall effect of all PFAS on DXA percentage fat in the positive or negative direction (positive and negative weights, respectively, add up to 1, representing the proportion of the overall effect and the relative importance of each mixture component within each direction; the shading of bars represents the overall effect size within each direction, with darker shades indicating a larger effect compared to lighter shades; estimates are provided in Table S8). Panel C shows the estimates and 95% credible intervals of PFAS with DXA percentage fat when all other PFAS are fixed at their 50<sup>th</sup> percentile.

**Figure S8.** Multivariable-adjusted associations between individual prenatal PFAS and DXA fat mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence estimated using (A) linear regression, (B) quantile g-computation, and (C) Bayesian kernel machine regression ( $n = 439$ ). Panel A shows the differences and 95% confidence intervals of DXA fat mass index per doubling of PFAS levels (estimates are provided in Table 3 [Adjusted]). Panel B shows the weights for each PFAS that correspond to the proportion of the overall effect of all PFAS on DXA fat mass index in the positive or negative direction (positive and negative weights, respectively, add up to 1, representing the proportion of the overall effect and the relative importance of each mixture component within each direction; the shading of bars represents the overall effect size within each direction, with darker shades indicating a larger effect compared to lighter shades; estimates are provided in Table S8). Panel C shows the estimates and 95% credible intervals of PFAS with DXA fat mass index when all other PFAS are fixed at their 50<sup>th</sup> percentile.

**Figure S9.** Multivariable-adjusted associations between individual prenatal PFAS and DXA trunk fat mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence estimated using (A) linear regression, (B) quantile g-computation, and (C) Bayesian kernel machine regression ( $n = 439$ ). Panel A shows the differences and 95% confidence intervals of DXA trunk fat mass index per doubling of PFAS levels (estimates are provided in Table 3 [Adjusted]). Panel B shows the weights for each PFAS that correspond to the proportion of the overall effect of all PFAS on DXA trunk fat mass index in the positive or negative direction (Positive and negative weights respectively add up to 1, representing the proportion of the overall effect and the relative importance of each mixture component within each direction; estimates are provided in Table S8). Panel C shows the estimates and 95% credible intervals of PFAS with DXA trunk fat mass index when all other PFAS are fixed at their 50<sup>th</sup> percentile.

**Figure S10.** Multivariable-adjusted associations between individual prenatal PFAS and DXA lean mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence estimated using (A) linear regression, (B) quantile g-computation, and (C) Bayesian kernel machine regression ( $n = 439$ ). Panel A shows the differences and 95% confidence intervals of DXA lean mass index per doubling of PFAS levels (estimates are provided in Table 3 [Adjusted]). Panel B shows the weights for each PFAS that correspond to the proportion of the overall effect of all PFAS on DXA lean mass index in the positive or negative direction (positive and negative weights, respectively, add up to 1, representing the proportion of the overall effect and the relative importance of each mixture component within each direction; the shading of bars represents the overall effect size within each direction, with darker shades indicating a larger effect compared to lighter shades; estimates are provided in Table S8). Panel C shows the estimates and 95% credible intervals of PFAS with DXA lean mass index when all other PFAS are fixed at their 50<sup>th</sup> percentile.

**Figure S11.** Associations between prenatal PFAS 1 concentrations (columns) and BMI ( $\text{kg}/\text{m}^2$ ) in late adolescence by levels (10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile) of prenatal PFAS 2 concentration (rows) when all other PFAS are fixed at their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 545$ ).

**Figure S12.** Associations between prenatal PFAS 1 concentrations (columns) and DXA percentage fat in late adolescence by levels (10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile) of prenatal PFAS 2 concentration (rows) when all other PFAS are fixed at their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 439$ ).

**Figure S13.** Associations between prenatal PFAS 1 concentrations (columns) and DXA fat mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence by levels (10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile) of prenatal PFAS 2 concentration (rows) when all other PFAS are fixed at their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 439$ ).

**Figure S14.** Associations between prenatal PFAS 1 concentrations (columns) and DXA trunk fat mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence by levels (10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile) of prenatal PFAS 2 concentration (rows) when all other PFAS are fixed at their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 439$ ).

**Figure S15.** Associations between prenatal PFAS 1 concentrations (columns) and DXA lean mass index ( $\text{kg}/\text{m}^2$ ) in late adolescence by levels (10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile) of prenatal PFAS 2 concentration (rows) when all other PFAS are fixed at their 50<sup>th</sup> percentile estimated using Bayesian kernel machine regression ( $n = 439$ ).

**Figure S16.** Fractional polynomial prediction plots showing the association between age and body mass index across childhood and adolescence by prenatal PFOS, EtFOSAA, and MeFOSAA levels stratified by child sex (male [ $n = 616$ ] vs. female [ $n = 540$ ]). “Higher” was defined as PFAS levels above the population median, and “lower” was defined as PFAS levels below the population median. Median levels were 25.70 ng/mL for PFOS, 1.20 ng/mL for EtFOSAA, and 1.90 ng/mL for MeFOSAA.

**Additional File-** Excel Document